Although most tumors progress and maintain AR dependency, approximately 15% to 20% patients will progress where their tumor is indifferent to AR signaling (CRPC-AI) and activate developmental programs related to stemness and pluripotency (phenotypic plasticity). Here, AR is linked to neoplasm.